论文部分内容阅读
目的:观察利伐沙班与华法林对心房颤动(房颤)伴左心房血栓形成患者的溶栓疗效及安全性。方法:选取在我院就诊并确诊为有血栓形成的非瓣膜性房颤患者40例,按患者入院时间随机分为利伐沙班组20例和华法林组20例,利伐沙班组患者应用利伐沙班进行治疗,华法林组患者应用华法林进行治疗,观察期为6个月。比较两组患者左心房血栓溶解率、血栓栓塞率及出血发生率。结果:利伐沙班组附壁血栓溶解率85.0%,华法林组附壁血栓溶解率70.0%,两组比较差异无统计学意义(P>0.05);利伐沙班组血栓栓塞率5%,华法林组血栓栓塞率5%,两组比较差异无统计学意义(P>0.05)。利伐沙班组出血率5.0%,华法林组出血率10.0%,两组比较差异亦无统计学意义(P>0.05)。结论:利伐沙班在非瓣膜性房颤伴左心房血栓形成患者中溶解左心房血栓的疗效方面与华法林一致,血栓栓塞和出血风险两者比较没有显著的差异。
Objective: To observe the efficacy and safety of rivaroxaban and warfarin on thrombolytic therapy in patients with atrial fibrillation (AF) and left atrial thrombosis. Methods: Forty patients with non-valvular atrial fibrillation who were diagnosed as thrombosis and were diagnosed as thrombosis were randomly divided into rivaroxaban 20 cases and warfarin 20 cases according to the time of admission. The patients in rivaroxaban group Rivaroxaban for treatment, warfarin group patients treated with warfarin, the observation period of 6 months. Left atrial thrombosis dissolution rate, thromboembolism rate and incidence of bleeding were compared between the two groups. Results: The dissolution rate of mural thrombus in rivaroxaban group was 85.0%, and the rate of the thrombolytic activity in the warfarin group was 70.0%. There was no significant difference between the two groups (P> 0.05) Warfarin group thromboembolism rate of 5%, no significant difference between the two groups (P> 0.05). Bleeding rate in rivaroxaban group was 5.0% and that in warfarin group was 10.0%. There was no significant difference between the two groups (P> 0.05). CONCLUSIONS: Rivaroxaban is consistent with warfarin in treating left atrial thrombi in patients with non-valvular atrial fibrillation and left atrial thrombosis, with no significant difference in risk of thromboembolism and bleeding.